ahlam1399
09-01-2015, 11:25 AM
Valeant gets right to develop AstraZeneca?s psoriasis drug
(Reuters) - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.
http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2.img (http://da.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/ach.img (http://adchoice.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/ach.htm)http://pi.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2t.imghttp://pi2.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4976b924/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=dMDS6hu4e8E:wWP0kpLy7bQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dMDS6hu4e8E:wWP0kpLy7bQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=dMDS6hu4e8E:wWP0kpLy7bQ:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dMDS6hu4e8E:wWP0kpLy7bQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=dMDS6hu4e8E:wWP0kpLy7bQ:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/dMDS6hu4e8E
(Reuters) - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.
http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2.img (http://da.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/ach.img (http://adchoice.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/ach.htm)http://pi.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2t.imghttp://pi2.feedsportal.com/r/238385010938/u/49/f/654207/c/35217/s/4976b924/sc/21/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4976b924/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=dMDS6hu4e8E:wWP0kpLy7bQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dMDS6hu4e8E:wWP0kpLy7bQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=dMDS6hu4e8E:wWP0kpLy7bQ:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dMDS6hu4e8E:wWP0kpLy7bQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=dMDS6hu4e8E:wWP0kpLy7bQ:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/dMDS6hu4e8E